It was also approved to be one of the first-line treatment options for EGFR-mutant NSCLC patients owing to the positive results from the FLAURA study, which demonstrated significant survival benefits in both PFS and OS [13, 14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.